Cytosorbents Corp
CTSO0.637USD
-0.008-1.26%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
39.99MMarket Cap
LossP/E TTM
More Details of Cytosorbents Corp Company
CytoSorbents Corporation is engaged in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery through blood purification. The Company’s blood purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Its lead product, CytoSorb, is an extracorporeal blood purification cartridge to reduce cytokine storms in common critical illnesses that can lead to massive inflammation, organ failure and patient death. Its products also include ECOS-300CY, VetResQ, DrugSorb-ATR, and PuriFi. DrugSorb-ATR is an investigational device that uses equivalent polymer technology to CytoSorb to address a large unmet need for blood thinner reversal in cardiothoracic surgery. ECOS-300CY is used to reduce cytokines and other inflammatory mediators when used in an ex vivo organ perfusion system.
Cytosorbents Corp Info
Ticker SymbolCTSO
Company nameCytosorbents Corp
IPO dateJun 17, 2005
CEOChan (Phillip P)
Number of employees149
Security typeOrdinary Share
Fiscal year-endJun 17
Address305 College Road East
CityPRINCETON
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code08540
Phone19733298885
Websitehttps://cytosorbents.com/
Ticker SymbolCTSO
IPO dateJun 17, 2005
CEOChan (Phillip P)
Company Executives of Cytosorbents Corp
Name
Name/Position
Position
Shareholding
Change
Dr. Phillip P. Chan, M.D., Ph.D.
Dr. Phillip P. Chan, M.D., Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
1.17M
+9.31%
Mr. Vincent J. Capponi
Mr. Vincent J. Capponi
President, Chief Operating Officer
President, Chief Operating Officer
1.11M
+8.76%
Mr. Peter J. (Pete) Mariani, CPA
Mr. Peter J. (Pete) Mariani, CPA
Chief Financial Officer
Chief Financial Officer
188.11K
+61.31%
Mr. Alan D. Sobel, CPA
Mr. Alan D. Sobel, CPA
Independent Director
Independent Director
78.46K
--
Ms. Jiny Kim
Ms. Jiny Kim
Independent Director
Independent Director
8.52K
--
Dr. Efthymios N. Deliargyris, M.D.
Dr. Efthymios N. Deliargyris, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Edward R. Jones, M.D.
Dr. Edward R. Jones, M.D.
Independent Director
Independent Director
--
--
Mr. Michael G. Bator
Mr. Michael G. Bator
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Phillip P. Chan, M.D., Ph.D.
Dr. Phillip P. Chan, M.D., Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
1.17M
+9.31%
Mr. Vincent J. Capponi
Mr. Vincent J. Capponi
President, Chief Operating Officer
President, Chief Operating Officer
1.11M
+8.76%
Mr. Peter J. (Pete) Mariani, CPA
Mr. Peter J. (Pete) Mariani, CPA
Chief Financial Officer
Chief Financial Officer
188.11K
+61.31%
Mr. Alan D. Sobel, CPA
Mr. Alan D. Sobel, CPA
Independent Director
Independent Director
78.46K
--
Ms. Jiny Kim
Ms. Jiny Kim
Independent Director
Independent Director
8.52K
--
Dr. Efthymios N. Deliargyris, M.D.
Dr. Efthymios N. Deliargyris, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
CytoSorb and other sales
9.62M
0.00%
By RegionUSD
Name
Revenue
Proportion
All other
6.20M
64.48%
Germany
3.35M
34.89%
United States
61.00K
0.63%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
CytoSorb and other sales
9.62M
0.00%
Shareholding Stats
Updated: Tue, Nov 25
Updated: Tue, Nov 25
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Avenir Corporation
8.09%
Rokk LLC
6.39%
Satterfield (Thomas A Jr)
4.60%
The Vanguard Group, Inc.
3.51%
Skylands Capital, LLC
3.39%
Other
74.02%
Shareholders
Shareholders
Proportion
Avenir Corporation
8.09%
Rokk LLC
6.39%
Satterfield (Thomas A Jr)
4.60%
The Vanguard Group, Inc.
3.51%
Skylands Capital, LLC
3.39%
Other
74.02%
Shareholder Types
Shareholders
Proportion
Investment Advisor
17.70%
Individual Investor
9.21%
Corporation
6.39%
Investment Advisor/Hedge Fund
4.33%
Hedge Fund
3.94%
Research Firm
0.20%
Bank and Trust
0.03%
Other
58.19%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
98
16.29M
29.02%
--
2025Q3
105
16.36M
29.12%
-250.79K
2025Q2
114
16.81M
30.05%
-683.16K
2025Q1
120
17.53M
28.41%
-230.06K
2024Q4
120
16.37M
34.77%
-1.42M
2024Q3
120
17.79M
36.10%
-511.38K
2024Q2
137
18.34M
39.80%
-1.26M
2024Q1
170
19.60M
43.42%
-3.07M
2023Q4
184
20.73M
36.88%
+3.89M
2023Q3
200
16.89M
48.07%
-69.58K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Avenir Corporation
5.06M
8.06%
+13.62K
+0.27%
Jun 30, 2025
Rokk LLC
4.02M
6.4%
--
--
Apr 17, 2025
Satterfield (Thomas A Jr)
2.89M
4.6%
+2.89M
--
Jan 13, 2025
The Vanguard Group, Inc.
2.12M
3.39%
+175.21K
+8.99%
Jun 30, 2025
Skylands Capital, LLC
2.62M
4.17%
-385.99K
-12.85%
Jun 30, 2025
Neuberger Berman, LLC
1.59M
2.54%
-87.94K
-5.24%
Jun 30, 2025
CM Management, LLC
1.25M
1.99%
+295.92K
+31.02%
Jun 30, 2025
Chan (Phillip P)
1.07M
1.71%
+105.60K
+10.90%
Aug 08, 2025
Capponi (Vincent J)
1.11M
1.76%
+89.10K
+8.76%
Aug 08, 2025
BlackRock Institutional Trust Company, N.A.
736.37K
1.17%
+109.16K
+17.40%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Micro-Cap ETF
0.01%
iShares Micro-Cap ETF
Proportion0.01%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Cytosorbents Corp?
The top five shareholders of Cytosorbents Corp are:
Avenir Corporation holds 5.06M shares, accounting for 8.06% of the total shares.
Rokk LLC holds 4.02M shares, accounting for 6.40% of the total shares.
Satterfield (Thomas A Jr) holds 2.89M shares, accounting for 4.60% of the total shares.
The Vanguard Group, Inc. holds 2.12M shares, accounting for 3.39% of the total shares.
Skylands Capital, LLC holds 2.62M shares, accounting for 4.17% of the total shares.
Avenir Corporation holds 5.06M shares, accounting for 8.06% of the total shares.
Rokk LLC holds 4.02M shares, accounting for 6.40% of the total shares.
Satterfield (Thomas A Jr) holds 2.89M shares, accounting for 4.60% of the total shares.
The Vanguard Group, Inc. holds 2.12M shares, accounting for 3.39% of the total shares.
Skylands Capital, LLC holds 2.62M shares, accounting for 4.17% of the total shares.
What are the top three shareholder types of Cytosorbents Corp?
The top three shareholder types of Cytosorbents Corp are:
Avenir Corporation
Rokk LLC
Satterfield (Thomas A Jr)
Avenir Corporation
Rokk LLC
Satterfield (Thomas A Jr)
How many institutions hold shares of Cytosorbents Corp (CTSO)?
As of 2025Q4, 98 institutions hold shares of Cytosorbents Corp, with a combined market value of approximately 16.29M, accounting for 29.02% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -0.10%.
What is the biggest source of revenue for Cytosorbents Corp?
In FY2025Q2, the CytoSorb and other sales business generated the highest revenue for Cytosorbents Corp, amounting to 9.62M and accounting for --% of total revenue.
